MarketInOut Stock Screener Log In | Sign Up
 

Lineage Cell Therapeutics Inc

NYSE • Healthcare • Biotechnology • Quote as of 06/15/2026 15:10
Lineage Cell Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization316.61 mln
Float187 mln
Earnings Date08/06/2026

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-0.32
Highly suspicious

Relative Strength

25 / 100
Underperforming

Debt / Equity

0.04
Debt-free

ROE

-130
Deeply negative

Dividend Yield

0.00%
No dividend

Business Description

Lineage Cell Therapeutics is a California-based biotechnology company focused on developing therapies that replace damaged or lost cells to treat serious conditions affecting vision, hearing, the nervous system, and metabolism. Its most advanced programs include a retinal cell therapy for age-related macular degeneration and a nerve cell therapy for spinal cord injuries, both currently in clinical trials. The company also has several earlier-stage programs in development, targeting conditions such as hearing loss, diabetes, and photoreceptor damage, and works with outside partners to advance some of these efforts. Formerly known as BioTime Inc., the company has been operating since 1990.

Key Fundamentals

EPS-0.29
ROE-130
RPS0.06
ROIC-37.84
ROA-62.42
EBITDA, mln-22.14
EV / EBITDA-12.05
EV / EBIT-11.67
Revenue, mln14.78
EV / Revenue18.06

Financial Strength

Altman Z-Score-4.06
Piotroski F-Score 4 / 9
Beneish M-Score-0.32
Short Ratio18.80
Short % of Float17.52

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 2.48% 60 / 100   
1 Month -5.34% 15 / 100   
2 Months -29.94% 3 / 100   
6 Months -27.49% 7 / 100   
1 Year 76.51% 92 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us